CN Patent

CN1315853A — 在口服固体剂型中包含依普沙坦的生物利用度提高的制剂

Assigned to SmithKline Beecham Corp · Expires 2001-10-03 · 25y expired

What this patent protects

本发明涉及包含非晶体形式依普沙坦或依普沙坦甲磺酸盐的生物利用度提高的制剂,其制备方法,含有该化合物的组合物,和使用该化合物阻断血管紧张素Ⅱ受体以及治疗高血压、充血性心力衰竭和肾衰竭的方法。

USPTO Abstract

本发明涉及包含非晶体形式依普沙坦或依普沙坦甲磺酸盐的生物利用度提高的制剂,其制备方法,含有该化合物的组合物,和使用该化合物阻断血管紧张素Ⅱ受体以及治疗高血压、充血性心力衰竭和肾衰竭的方法。

Drugs covered by this patent

lazertinib-mesylate (LAZERTINIB MESYLATE)

Patent Metadata

Patent number: CN1315853A
Jurisdiction: CN
Classification: —
Expires: 2001-10-03
Drug substance claim: No
Drug product claim: No
Assignee: SmithKline Beecham Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.